JNJ Stock Discussion (Johnson & Johnson)

J&J reports surgery-comparator benefit for Erleada in prostate cancer

Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen reduced the risk of biochemical failure, recurrence, metastasis or death by 62%. At three years, 63% remained event-free, versus 41.4% in the surgery-only group. The separate comparison adds evidence beyond the main PROTEUS results disclosed earlier and could

JNJ

@tickerstat12 days ago

J&J reports early prostate-cancer responses for experimental oral drug

Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occurred in 69% of patients with measurable lesions, a separate assessment population. Common adverse effects included nausea and increased blood lipids. The compound is designed to link the androgen receptor with BRD4, a protein needed for cell survival, and is be

JNJ

@tickerstat1 month ago

Carvykti follow-up finds half of a small cohort progression-free at five years

Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after a single infusion. The cohort included patients with relapsed or refractory multiple myeloma after one to three previous treatment lines; estimated five-year overall survival was 69.2%. Median progression-free survival reached 60.5 months. Since the earlier an

JNJ

@tickerstat1 month ago

Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals

Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo on the BASDAI disease-activity measure at week 24, together with positive findings on an additional disease-activity assessment and MRI measures of inflammation. The announcement did not provide numerical effect sizes, with detailed results reserved for a futu

JNJ

@tickerstat1 month ago

Apollo reportedly nears $20 billion talks for J&J orthopedics business

Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in sales in 2025. A deal could emerge within weeks, but negotiations are not a signed acquisition. Johnson & Johnson is also considering its planned separation of the business. The report leaves the final structure, financing and outcome unresolved; neither comp